The latest update is out from Theralase Technologies ( (TSE:TLT) ).
Theralase Technologies has announced that independent research by the University of Manitoba has verified that Ruvidar, a small molecule developed by the company, is significantly more effective than acyclovir in inactivating Herpes Simplex Viruses post-infection. This finding could have significant implications for the treatment of herpes simplex viruses, as Ruvidar was shown to inhibit viral replication at lower concentrations and demonstrated additive and synergistic effects in combination therapy.
More about Theralase Technologies
Theralase Technologies Inc. is a clinical stage pharmaceutical company focused on the research and development of light, radiation, sound, and drug-activated small molecules and their formulations. These are intended for the safe and effective destruction of various cancers, bacteria, and viruses.
YTD Price Performance: -3.57%
Average Trading Volume: 101,008
Technical Sentiment Consensus Rating: Sell
Current Market Cap: C$66.9M
Find detailed analytics on TLT stock on TipRanks’ Stock Analysis page.